KNSAKiniksa Pharmaceuticals International, plc
$79.76+125% 1Y
$79.76
$35.5152 weeks$80.83
KNSA in its own filings
Nothing in KNSA's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
158
Events found in the filings · across 763 filings · the record starts in 2018
- Hard flags
- none
Hard flags
- Most recent filing
- Jul 28, 2026
Most recent filing · Form 8-K
- Record starts
- Mar 29, 2018
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Oct 27, 2026
- SEC comment-letter activity27 occurrences
- 2024-07-02
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Jul 28, 2026Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution.Earnings release · press release
- May 26, 2026On May 21, 2026, Kiniksa Pharmaceuticals International, plc (the “Company”) entered into a deed of waiver (the “Deed”) with Baker Bros. Advisors LP, on behalf of each of Baker Brothers Life Sciences, L.P. and 667, L.P. (the “Shareholders”), pursuant to which the Shareholders waived their rights to convert any of their …Material agreement entered · Form 8-K
- May 1, 2026On April 30, 2026, Eben Tessari informed Kiniksa Pharmaceuticals International, plc (the “Company”) of his decision to resign as Chief Strategy Officer of the Company to pursue another executive position within the life sciences industry.Director or officer change · Form 8-K
- Apr 28, 2026Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution.Earnings release · press release
- Feb 24, 2026Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution.Earnings release · press release
- Jan 14, 2026Effective January 10, 2026, the Board of Directors of Kiniksa Pharmaceuticals International, plc (the “Company”) appointed Ross Moat to the position of Chief Operating Officer and principal operating officer.Director or officer change · Form 8-K
- Jan 12, 2026Kiniksa Pharmaceuticals Provides Corporate Update.Earnings release · press release
- Oct 28, 2025Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
Drug Manufacturers, Specialty & Generic
Ranks #28 of 41 by RyuScore